Rigel Pharmaceuticals Announces New Employee Stock Grants Under NASDAQ Rule 5635(c)(4)

Rigel Pharmaceuticals Announces New Employee Stock Grants

On October 2, 2026, Rigel Pharmaceuticals, Inc. based in South San Francisco, California, confirmed that it has granted a total of 35,275 restricted stock units (RSUs) as part of its Inducement Plan. This move is compliant with NASDAQ Listing Rule 5635(c)(4), allowing the company to provide these stock awards as incentives to new hires joining the organization.

Details of the Stock Grants

The awarded stock units are aimed at 18 non-executive employees, vesting over a four-year period. Each year, 25% of the granted RSUs will become available to the respective employees. This structured vesting approach not only serves as a competitive compensation strategy but also encourages employee retention and commitment to Rigel's long-term growth.

About Rigel Pharmaceuticals

Founded in 1996, Rigel Pharmaceuticals is a leading biotechnology company focused on developing innovative therapies, particularly for patients suffering from hematological disorders and various types of cancer. With a strong commitment to medical advancement, Rigel has positioned itself as a player in the biotech industry, delivering potential breakthrough treatments to improve patient lives. The company is publicly traded under the NASDAQ symbol RIGL.

For more information regarding Rigel's product offerings and ongoing research projects, individuals interested can visit their official website at www.rigel.com.

Implications of the Inducement Grants

The decision to grant these stock awards underscores Rigel's strategic aim to attract top talent into its ranks. In the highly competitive biotech sector, especially when it comes to roles linked to drug discovery and development, effective talent management becomes a pivotal initiative. By providing stock options, Rigel not only enhances its compensation package but also aligns employee interests with that of the company's overall success and shareholder value.

As Rigel continues to expand, maintaining an engaged and motivated workforce is essential. Grants such as these are instrumental in fostering an environment where employees feel valued and part of a larger mission, thus likely boosting overall productivity and workplace morale.

Looking Forward

With this initiative, Rigel Pharmaceuticals clearly articulates its intent to reinforce its team with skilled professionals committed to their fight against diseases like cancer. The biotechnology landscape is rapidly evolving, and companies like Rigel are at the forefront of this transformation. Investors and stakeholders will be watching closely to see how this and other employee initiatives will contribute to the company’s trajectory.

Rigel’s commitment to its employees through these stock awards reflects an understanding that a successful company is built on the foundation of its people. As long as Rigel maintains this vision, its potential for continuous growth and innovation remains promising.